Browse

Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer

Cited 26 time in Web of Science Cited 36 time in Scopus
Authors
Seo, Myung-Deok; Lee, Keun-Wook; Lim, Joo Han; Yi, Hyeon Gyu; Kim, Dae-Young; Oh, Do-Youn; Kim, Jee Hyun; Im, Seock-Ah; Kim, Tae-You; Lee, Jong Seok; Bang, Yung-Jue
Issue Date
2008-09
Publisher
Wiley-Blackwell
Citation
Japanese Journal of Clinical Oncology, Vol.38 No.9, pp.589-595
Keywords
gastric cancerchemotherapysecond-lineirinotecanFOLFIRI
Abstract
Objective: We analysed the efficacy and toxicity of irinotecan, leucovorin and 5-fluorouracil (FOLFIRI) chemotherapy as second-line treatment for metastatic or relapsed gastric cancer (MRGC) in a clinical practice setting. Factors to select patients who may benefit from salvage chemotherapy was also analysed. Methods: Patients with MRGC with progression on or within 6 months after discontinuing platinum-based chemotherapy received FOLFIRI as second-line therapy. The FOLFIRI regimen consisted of irinotecan (180 mg/m(2); day 1) combined with leucovorin (200 mg/m(2)), followed by 5-fluorouracil (400 mg/m(2)) as a bolus and 600 mg/m(2) as a 22-h infusion on days 1 and 2 every 2 weeks. Results: Fifty-one patients received a total of 282 courses of chemotherapy. No patients had complete remission (CR), but 9 patients achieved partial remission (PR). Stable disease (SD) was documented in 15 patients. The median progression-free survival (PFS) and overall survival (OS) were 3.2 and 9.1 months, respectively. Toxicities were tolerable and grade 3/4 neutropenia was observed in 49 cycles (17%). In multivariate analysis, patients with less organ involvement by metastasis and good performance status (PS) were independently associated with a longer PFS and OS (P < 0.05). Disease control (CR, PR or SD) after first-line chemotherapy were related to a longer PFS (P = 0.02), but had no effect on OS. Conclusions: FOLFIRI was tolerable and showed modest activity as a second-line therapy in MRGC. Less organ involvement by metastasis or good PS may be optimal selection criteria for patients with MRGC who are suitable for second-line chemotherapy.
ISSN
0368-2811
Language
English
URI
https://hdl.handle.net/10371/62211
DOI
https://doi.org/10.1093/jjco/hyn078
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse